Research report

AUSPICIOUS LABORATORY, INC. | CLINICAL RESEARCH & EPIDEMIOLOGICAL REVIEW

West Houston STD Sample Study 2025–2026

A Retrospective Analysis of Urogenital Pathogen and Commensal Detection in Outpatient Testing at Auspicious Laboratory

Single-Center Retrospective Observational Review
Houston Westchase Location
Cohort Interval: January 1, 2025 – September 27, 2026
Published: September 2026

36.9%

Ureaplasma urealyticum

139 / 377 valid resultsCommon in healthy people; detection does not establish infection

32.4%

Gardnerella vaginalis

127 / 392 valid resultsA positive result alone does not diagnose BV (CDC)

15.8% vs. 4.2%

Composite STI Positivity

Age <35 vs. ≥35 (p < 0.001)Significant difference in core-STI positivity by age

1. Executive Summary

Multiplex nucleic acid amplification testing (NAAT) facilitates high-sensitivity, high-throughput identification of obligate sexually transmitted pathogens alongside endogenous and opportunistic urogenital microflora. However, broad syndromic molecular testing panels frequently generate diagnostic uncertainty when commensal organisms are inappropriately conflated with clinical disease. This retrospective review examines molecular urogenital testing records from 465 outpatient encounters submitted to Auspicious Laboratory (Houston Westchase) between January 2025 and September 2026.

The primary clinical objectives of this epidemiological assessment are to:

Quantify target-specific molecular detection rates in an ambulatory patient cohort.
Characterize the fundamental diagnostic distinction between obligate STIs and commensal urogenital colonizers.
Evaluate age-stratified positivity patterns across core sexually transmitted pathogens.
Reinforce clinical guidelines regarding diagnostic window periods, specimen collection heterogeneity, and antimicrobial stewardship.

Table 1. Target Detection Rates, Confidence Intervals, and Clinical Categorization
Target Organism / Measure	Counts (n / N)	Positivity (95% CI)	Interpretation & Classification
Any core STI (CT, NG, TV, MG)	46 / 388	11.9% (9.0% – 15.5%)	Composite detection of core sexually transmitted pathogens.
Mycoplasma genitalium (MG)	17 / 388	4.4% (2.8% – 6.9%)	Recognized STI pathogen; macrolide resistance markers reported in 44%–90% (CDC).
Neisseria gonorrhoeae (NG)	11 / 399	2.8% (1.5% – 4.9%)	Core bacterial STI pathogen requiring targeted clinical management.
Trichomonas vaginalis (TV)	10 / 391	2.6% (1.4% – 4.6%)	Parasitic protozoan STI; omitted from standard frontline CT/NG assays.
Chlamydia trachomatis (CT)	9 / 402	2.2% (1.2% – 4.2%)	Core bacterial STI pathogen requiring targeted clinical management.
Ureaplasma urealyticum (UU)	139 / 377	36.9% (32.2% – 41.8%)	Commonly found in healthy people; detection does not establish infection. CDC advises against testing for Ureaplasma.
Gardnerella vaginalis (GV)	127 / 392	32.4% (28.0% – 37.2%)	Associated with bacterial vaginosis (BV), but a positive Gardnerella result alone does not diagnose BV (CDC). Diagnosis requires clinical criteria.
Mycoplasma hominis (MH)	31 / 388	8.0% (5.7% – 11.1%)	Commonly found in healthy people; detection does not establish infection. The European STI Guidelines Editorial Board does not recommend routine testing.
Composite 4-STI (<35 years)	38 / 241	15.8% (11.7% – 20.9%)	Test panels from patients under 35 with complete panels. Significantly elevated positivity in young adults.
Composite 4-STI (≥35 years)	6 / 144	4.2% (1.9% – 8.8%)	Test panels from patients age 35 and older (χ² ≈ 12.0, p < 0.001 vs. <35 cohort).
TV or MG detected when CT and NG were not detected (first visits)	25 / 318	7.9% (5.4% – 11.3%)	Suggest patient not only test chlamydia and gonorrhea, but also TV and MG.

Note: Confidence intervals represent descriptive 95% Wilson score intervals. Composite 4-STI includes Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium. Differences among the four individual STI positivity rates are small and are not statistically significant. These figures describe testing at a single laboratory and do not represent population prevalence.

2. Pathogen Classification & Clinical Management Guidelines

A fundamental imperative of modern molecular diagnostics is preventing unnecessary antimicrobial exposure driven by the hyper-sensitivity of molecular amplification. To guide clinicians and interpreting personnel, targets analyzed in this review are categorized into two distinct operational groups:

Group 1: Obligate Sexually Transmitted Pathogens

Includes Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), Trichomonas vaginalis (TV), and Mycoplasma genitalium (MG). These are recognized sexually transmitted pathogens. The CDC 2021 STI Treatment Guidelines describe management, including treatment, partner services, and follow-up. Decisions about care rest with the treating clinician. For M. genitalium, CDC reports macrolide-resistance markers in 44% to 90% of infections, a finding reflected in the guidelines’ treatment recommendations.

Group 2: Commensal and Opportunistic Organisms

Includes Gardnerella vaginalis (GV), Ureaplasma urealyticum (UU), and Mycoplasma hominis (MH). These organisms are commonly recovered from the mucosal surfaces of healthy, asymptomatic individuals as part of normal microbial flora:

Ureaplasma urealyticum & Mycoplasma hominis: Detection alone does not constitute an infection. CDC advises against testing for Ureaplasma, and the European STI Guidelines Editorial Board does not recommend routine testing or treatment for M. hominis or Ureaplasma in men or women.
Gardnerella vaginalis: However, according to CDC, a positive Gardnerella result alone does not diagnose BV. Clinical diagnosis of BV requires meeting Amsel criteria (thin homogenous discharge, clue cells >20%, pH >4.5, positive whiff test) or a standardized Nugent Gram-stain score (7–10).

3. Diagnostic Window Periods & Clinical Timing

Molecular NAAT panels achieve analytical limits of detection in the order of copies/mL; nevertheless, diagnostic sensitivity remains physiologically bounded by the biological incubation period. Testing performed prematurely after sexual exposure may yield negative results despite organism transmission.

Table 2. Diagnostic Window Periods and Timing Benchmarks
Diagnostic Target	Average Window Period	Notes
Chlamydia & Gonorrhea (NAAT)	5 to 14 days	Earliest detection at 5 days; optimal diagnostic sensitivity achieved at 14 days post-exposure.
Trichomonas vaginalis & M. genitalium	2 to 4 weeks	Variable incubation periods; repeat evaluation recommended if initial early post-exposure screen is negative.
HIV-1/2 4th Gen Ag/Ab Immunoassay	18 to 45 days (Venous blood)	Detects p24 antigen and HIV antibodies. Finger-stick rapid tests require up to 90 days for peak sensitivity.
Post-Exposure Prophylaxis (nPEP)	Within 72 hours (Emergent)	Critical window: nPEP must be initiated within 72 hours of potential exposure. Do not delay therapy pending laboratory NAAT results.

Source note: HIV testing windows and PEP timing are from CDC (Getting Tested for HIV; Preventing HIV with PEP). The chlamydia/gonorrhea and TV/MG ranges are commonly cited clinical estimates; CDC does not publish formal window periods for these tests.

Clinical Alert Regarding HIV PEP: Laboratory diagnostic testing is an elective diagnostic modality, not an acute prophylaxis provider. In any clinical encounter reporting possible high-risk sexual or bloodborne HIV exposure within the preceding 72 hours, patients must be directed immediately to an acute medical clinic or emergency department for non-occupational post-exposure prophylaxis (nPEP) evaluation without waiting for routine laboratory processing.

4. Materials & Methods

Study Design & Cohort: A single-center retrospective observational study of 465 accessions logged at Auspicious Laboratory (Houston Westchase, TX) between January 1, 2025, and September 27, 2026.
Analytical Platform: A multiplex real-time polymerase chain reaction (RT-PCR) STI panel targeting C. trachomatis, N. gonorrhoeae, T. vaginalis, M. genitalium, U. urealyticum, M. hominis, and G. vaginalis, among other targets; blood-based HIV antigen/antibody testing.
Specimen Types: Urine specimens in 2025; urine or swab specimens in 2026, recorded as ‘Urine/Swab’ without an anatomical collection site; and blood specimens for HIV testing.
Statistical Analyses: Target positivity was computed as target-positive specimens divided by valid performed results (n/N). Two-sided 95% confidence intervals were generated utilizing the Wilson score interval. Differences between age strata (<35 vs. ≥35 years) across complete 4-STI panels were evaluated using Pearson’s chi-square test of independence (α = 0.05).

5. Methodological Limitations & Epidemiological Scope

1. Non-Probability Ambulatory Cohort (Selection Bias): The study population comprises individuals presenting voluntarily or referred for commercial outpatient diagnostic workups. Findings describe detection rates within a tested ambulatory sample and cannot be extrapolated as general community prevalence estimates for West Houston.

2. Specimen and Anatomical Heterogeneity: The accession records combine urine specimens from 2025 with urine or swab specimens from 2026, for which the anatomical collection site was not recorded. Colonization dynamics differ significantly between anatomical sites.

3. Absence of Clinical Metadata: Electronic requisition records did not include standardized diagnostic symptom scoring (discharge, dysuria, pelvic pain), physical examination findings, or documented exposure chronologies.

4. Clustered Non-Independence (Repeat Encounters): The aggregate dataset includes longitudinal re-evaluations and tests-of-cure. While sub-analyses controlled for initial visits (e.g., secondary TV/MG screening), pooled encounter metrics must be interpreted as specimen-level yields rather than unique individual person-level prevalence.

6. Key Clinical References

1. Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021: Mycoplasma genitalium. MMWR Recomm Rep. 2021;70(4):1–187.

2. Centers for Disease Control and Prevention (CDC). Urethritis and Cervicitis. STI Treatment Guidelines, 2021. https://www.cdc.gov/std/treatment-guidelines/urethritis-and-cervicitis.htm

3. Horner P, Donders G, Cusini M, et al. Should we be testing for urogenital Mycoplasma hominis, Ureaplasma parvum and Ureaplasma urealyticum in men and women? A position statement from the European STI Guidelines Editorial Board. J Eur Acad Dermatol Venereol. 2018;32(11):1845–1851.

4. Centers for Disease Control and Prevention (CDC). Getting Tested for HIV; Preventing HIV with PEP. https://www.cdc.gov/hiv/

5. Torrone EA, Kruszon-Moran D, Morrison CS, et al. Prevalence of Urogenital Mycoplasma genitalium Infection, United States, 2017 to 2018 (NHANES). Sex Transm Dis. 2021;48(11):e160–e162.

6. Manhart LE, Denslow S, English HE, et al. Mycoplasma genitalium in the US (MyGeniUS): Surveillance Data From Sexual Health Clinics in 4 US Regions. Clin Infect Dis. 2023;77(10):1449–1459.

7. De-identified STI PCR panel and HIV test records, January 2025–September 2026 (HIPAA Safe Harbor).

Chinese edition: 中文版研究报告 · All reports: Research & Data Reports

How can I reach the lab privately?

Text is the fastest way to reach us.

💬 Text us 📞 Call us ✉️ Email us

Or send your details below — we will reply by text or email during open hours.